Moderna (Moderna) Short Interest

View and export this data going back to 2018. Start your Free Trial

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison

For the Biotechnology subindustry, Moderna's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna Short Interest Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Short Interest distribution charts can be found below:

* The bar in red indicates where Moderna's Short Interest falls into.

Moderna (Moderna) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany 0QF:Germany 0QF:Germany 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

Stephen Hoge	officer: President	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel	director, officer: Chief Executive Officer	320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres	officer: See Remarks	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson	officer: General Counsel and Secretary	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115